Publicaciones en las que colabora con Pablo Sarobe Ugarriza (19)

2024

  1. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

2021

  1. Advances in immunotherapy for hepatocellular carcinoma

    Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2015

  1. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance

    Liver Transplantation, Vol. 19, Núm. 9, pp. 937-944

2011

  1. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010

    Cancer Immunology, Immunotherapy

2009

  1. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes

    Scandinavian Journal of Immunology, Vol. 69, Núm. 2, pp. 80-89

2007

  1. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1282-1295

2005

  1. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

    Vaccine, Vol. 23, Núm. 27, pp. 3493-3499

2004

  1. MAGE antigens: Therapeutic targets in hepatocellular carcinoma?

    Journal of Hepatology

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

  2. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  3. Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses

    International Immunology, Vol. 15, Núm. 6, pp. 691-699

  4. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses

    Journal of Virology, Vol. 77, Núm. 20, pp. 10862-10871

2002

  1. Abnormal priming of CD4+ T cells by dendritic cells expressing hepatitis C virus core and E1 proteins

    Journal of Virology, Vol. 76, Núm. 10, pp. 5062-5070

2001

  1. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes

    Journal of Hepatology, Vol. 34, Núm. 2, pp. 321-329

  2. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity

    European Journal of Immunology, Vol. 31, Núm. 6, pp. 1780-1789

1999

  1. T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides

    International Immunology, Vol. 11, Núm. 12, pp. 2025-2033